Attenuation of SRC Kinase Activity Augments PARP Inhibitor–mediated Synthetic Lethality in <i>BRCA2</i> -altered Prostate Tumors
Goutam Chakraborty(National Centre for Cell Science), Philip W. Kantoff(Dana-Farber Brigham Cancer Center), Michael J. Morris(The University of Texas Southwestern Medical Center), Yuki Yoshikawa(Memorial Sloan Kettering Cancer Center), Daniel C. Danila, Gwo‐Shu Mary Lee(Dana-Farber Cancer Institute), Ying Z. Mazzu(Memorial Sloan Kettering Cancer Center), Lorelei A. Mucci(Harvard University), Konrad H. Stopsack(Memorial Sloan Kettering Cancer Center), Wassim Abida(Memorial Sloan Kettering Cancer Center), Nabeela Khan Patail(Memorial Sloan Kettering Cancer Center), Subhiksha Nandakumar(Memorial Sloan Kettering Cancer Center), Rahim Hirani(New York Medical College), Lina Jehane(Memorial Sloan Kettering Cancer Center), Mohammad Atiq(Memorial Sloan Kettering Cancer Center)
Cited by 21
Related Papers
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
|New England Journal of Medicine|2010|5.5k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Gene expression correlates of clinical prostate cancer behavior
|Cancer Cell|2002|2.5k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k